OncoMatch/Clinical Trials/NCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
Is NCT07108868 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAR-T cells targeting CD19 and CD22 for lymphoma.
Treatment: CAR-T cells targeting CD19 and CD22 — A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 expression (detected by flow cytometry or immunohistochemistry)
CD19 or CD22 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry
Required: CD22 expression (detected by flow cytometry or immunohistochemistry)
CD19 or CD22 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: systemic therapy
after two or more systemic therapies, including one approved in label CAR-T-cell or bispecific antibody treatment option or with contraindications for such treatments
Must have received: BTK inhibitor
Patients with r/r CLL after established and approved treatment options including therapy with BTK inhibitors have failed
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 500/μL; Absolute lymphocyte count < 200/µL at time of leukapheresis; Platelet count < 50,000 mm3 (platelet transfusion allowed)
Kidney function
Serum Creatinine Clearance (CrCl) < 45 mL/min
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
Cardiac function
Echocardiogram (ECHO) or multi-gated acquisition (MUGA) with left ventricular ejection fraction < 45%
See Exclusion Criteria 5, 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07108868 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and BTK inhibitor.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages